Compare BridgeBio Pharma Inc (BBIO) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares MSCI South Korea ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while iShares MSCI South Korea ETF trades at $172.04. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | EWY | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $219.20 |
52-Week Low | $47.29 | $71.22 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWY (iShares MSCI South Korea ETF) trades at $166.09, up 1.2% with a neutral technical signal. The ETF faces volatility from South Korea's AI and semiconductor exposure, with recent news highlighting both government support initiatives and significant market swings. Technical indicators show mixed signals with RSI at 75.01 suggesting overbought conditions while moving averages remain bullish.
The outlook remains cautious as South Korean equities navigate AI-driven volatility and regulatory changes. Goldman Sachs maintains strong conviction with 90% upside potential for Korean stocks, but recent ETF speculation curbs and semiconductor stock declines present near-term headwinds for EWY investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
